The approval of Zaynich highlights India’s growing capabilities in pharmaceutical innovation, which could enhance its global reputation and open new markets. However, the industry faces challenges such as high R&D costs, regulatory hurdles, and the need for advanced clinical research infrastructure. Sustained investment and policy support will be crucial for maintaining this momentum.